Winson Tang continues his work as the Vice President of Clinical Development at Sangamo Bioscience to this day. Dr. Tang joined Sangamo in 2010 after consulting for Amsterdam Molecular Therapeutics, where he oversaw the conduct of Phase 2/3 Glybera orphan drug registration trial. Glybera is a gene therapy product for congenital lipoprotein lipase deficiency and was subsequently approved for marketing by the European Medical Association. Glybera was the first and remains the only gene therapy product approved in the western world. Dr. Tang has been working in the development of new and improved treatments for a number of deadly diseases that affect people around the world.

For Winson Tang, the position in Clinical Development at Sangamo Bioscience is the continuation of a life’s work of developing and testing new treatments for diseases such as end stage renal disease, AIDS/HIV, diabetes, and rarer, so-called “orphan diseases” that only affect a small portion of the population in countries in Europe and the United States. In the US, some rare diseases are designated “orphan” and draw from a special fund set up by federal legislation decades ago. Researchers like Dr. Tang work to develop new ways of fighting these diseases so they can not only help the people suffering from them in the United States, but also discover new methods of treatment that could be used for other diseases.

Winson Tang had a long career as a physician/scientist before he came to Sangamo Bioscience. After earning a combined Master’s and Bachelor’s degree in Organic Chemistry by graduating magna cum laude from Tufts University in 4 years, Dr. Tang went on to earn his medical degree from the Albert Einstein College of Medicine. He completed an Internal Medicine residency at the University of Southern California and was selected as a Chief Medical Resident at USC. He completed post-doctoral training and study in Nephrology at the University of California San Diego and research training in Immunology at The Scripps Research Institute with an emphasis on renal immunology, inflammation, and fibrosis.

Winson Tang has helped develop several new therapies for a number of diseases including ESRD and HCV. As the Vice President of Clinical Development, Dr. Tang is responsible for all clinical development programs within the company.

To Learn More,Visit: https://vimeo.com/winsontang